Scientific Opinion on the substantiation of a health claim related to Yestimun® and immune responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Articolo
Data di Pubblicazione:
2010
Citazione:
Scientific Opinion on the substantiation of a health claim related to
Yestimun® and immune responses pursuant to Article 13(5) of Regulation
(EC) No 1924/2006 / E. Panel on Dietetic Products, N. Allergies, E. Panel on Dietetic Products, N. Allergies, E. Panel on Dietetic Products, N. Allergies, C.V. Agostoni, J.L. Bresson, S. Fairweather Tait, A. Flynn, I. Golly, H. Korhonen, P. Lagiou, M. Løvik, R. Marchelli, A. Martin, B. Moseley, M. Neuhäuser Berthold, H. Przyrembel, S. Salminen, Y. Sanz, S. Strain, S. Strobel, I. Tetens, D. Tomé, H. van Loveren, H. Verhagen. - In: EFSA JOURNAL. - ISSN 1831-4732. - 8:5(2010), pp. 1607-1-1607-11. [10.2903/j.efsa.2010.1607]
Abstract:
Following an application from Leiber GmbH submitted pursuant to Article 13(5) of Regulation (EC) No
1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies
was asked to deliver an opinion on the scientific substantiation of a health claim related to Yestimun® and the
initiation of appropriate innate and adaptive immune responses. The scope of the application was proposed to
fall under a health claim based on newly developed scientific evidence and including a request for the protection
of proprietary data. The Panel considers that the food, Yestimun®, which consists of (1,3)-(1,6)-β-D-glucans
from brewer’s yeast cell wall (100 % Saccharomyces cerevisiae), is sufficiently characterised. The target
population is adults. The Panel considers that the initiation of appropriate innate and adaptive immune responses
is a beneficial physiological effect. In weighing the evidence the Panel took into account that in the one human
intervention study conducted with Yestimun® from which scientific conclusions could be drawn for the
scientific substantiation of the claim, no effects of Yestimun® were observed on any outcome that could imply a
beneficial effect on the initiation of appropriate innate and adaptive immune responses, and that the evidence
provided in the animal and in vitro studies does not predict an effect of Yestimun® on the initiation of
appropriate innate and adaptive immune responses in humans. The Panel concludes that a cause and effect
relationship has not been established between the consumption of Yestimun® and the initiation of appropriate
innate and adaptive immune responses
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Yestimun® ; beta-glucans ; immune responses ; health claims
Elenco autori:
E. Panel on Dietetic Products, N. Allergies, E. Panel on Dietetic Products, N. Allergies, E. Panel on Dietetic Products, N. Allergies, C.V. Agostoni, J.L. Bresson, S. Fairweather Tait, A. Flynn, I. Golly, H. Korhonen, P. Lagiou, M. Løvik, R. Marchelli, A. Martin, B. Moseley, M. Neuhäuser Berthold, H. Przyrembel, S. Salminen, Y. Sanz, S. Strain, S. Strobel, I. Tetens, D. Tomé, H. van Loveren, H. Verhagen
Link alla scheda completa: